行情

APTX

APTX

Aptinyx
NASDAQ

实时行情|Nasdaq Last Sale

4.150
+0.160
+4.01%
盘后: 4.150 0 0.00% 16:00 12/06 EST
开盘
4.020
昨收
3.990
最高
4.220
最低
4.000
成交量
16.27万
成交额
--
52周最高
22.99
52周最低
2.610
市值
1.31亿
市盈率(TTM)
-2.4118
分时
5日
1月
3月
1年
5年

分析师评级

6位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

APTX 新闻

  • Aptinyx launches mid-stage NYX-458 study
  • Seeking Alpha - Article.2天前
  • Aptinyx Reports Initiation Of Phase 2 Study Of NYX-458 In Patients with Mild Cognitive Impairment Associated with Parkinson's Disease
  • Benzinga.2天前
  • Aptinyx Initiates Phase 2 Study of NYX-458 in Patients with Mild Cognitive Impairment Associated with Parkinsons Disease
  • GlobeNewswire.2天前
  • 法国兴业银行:美债收益率或将因衰退风险而跌至1.2%
  • 环球外汇网官网.4天前

更多

所属板块

制药
+0.45%
制药与医学研究
+0.49%

热门股票

名称
价格
涨跌幅

APTX 简况

Aptinyx Inc. is a clinical-stage biopharmaceutical company. The Company discovers and develops therapies for disorders of the brain and nervous system. The Company has a platform for discovering compounds that work through a mechanism, which includes modulation of the N-methyl-D-aspartate (NMDA) receptor to develop pathways involved with nerve cell communication. The Company's compounds are effective on disease models including, depression, neuropathic pain, migraine, traumatic brain injury and age-induced learning impairment. The Company's compounds facilitate receptor activation without over-activating the receptor. The Company’s lead product candidate is NYX-2925, a treatment for the painful diabetic peripheral neuropathy. It is also developing NYX-783 for the treatment of post-traumatic stress disorder and NYX-458 for Parkinson’s disease cognitive impairment. The Company in partnership with Allergan plc, develops AGN-241751 for major depressive disorder indications.
展开

Webull提供Aptinyx Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。